

Serum Endocan and Procalcitonin Levels in Determining The Severity of Acute Pancreatitis

Hatice Beyazal Polat¹, Medeni Arpa², Mehmet Beyazal³, Teslime Ayaz¹, Fatma Beyazal³, Filiz Mercantepe¹, M. Ali Ayvaz⁴, Halil Rakıcı⁴, A. Remzi Akdoğan⁴

¹ Recep Tayyip Erdogan University, Faculty of Medicine, Department of Internal Medicine, Rize, Turkey

² Recep Tayyip Erdogan University, Faculty of Medicine, Department of Biochemistry, Rize, Turkey

³ Recep Tayyip Erdogan University, Faculty of Medicine, Department of Radiodiagnostic, Rize, Turkey

⁴ Recep Tayyip Erdogan University, Faculty of Medicine, Department of Gastroenterology, Rize, Turkey

Yazışma Adresi / Correspondence:

Teslime Ayaz

Recep Tayyip Erdogan University Faculty of Medicine, Department of Internal Medicine, Rize, Turkey

T: +90 533 741 51 48 E-mail: drthess@hotmail.com

Öz

Amaç: Skorlama sistemleri ve görüntüleme yöntemleri, akut pankreatitin (AP) şiddetini belirlemede yeterli bilgi sağlayamayabilir, diğer parametrelere ihtiyaç vardır. İnflamasyon akut pankreatit patogenezinde önemlir rol oynar ve inflamasyon belirteçleri AP şiddetinin belirlenmesinde önemli olabilir.

Yöntem: İlk AP atağı olan ardışık 52 yetişkin hasta (> 18 yaş) prospektif olarak çalışmaya dahil edildi. Akut pankreatit ciddiyeti Revize Atlanta kriterlerine göre belirlendi. Dolaşımdaki endokan ve prokalsitonin (PCT) seviyeleri ELISA yöntemi kullanılarak ölçüldü.

Bulgular: İlk AP tanısı alan 52 sıralı yetişkin hasta AP ciddiyetine göre; 25 hasta hafif- AP (% 48), 27'si orta - şiddetli AP (% 52) olmak üzere 2 gruba ayrıldı. Ortalama hasta yaşı ve kadın cinsiyet oranı orta - şiddetli AP grubunda hafif AP grubuna göre anlamlı derecede yüksekti (sırasıyla $p = 0.04$ ve 0.02). Bununla birlikte, gruplar biyokimyasal parametreler açısından anlamlı farklılık göstermedi ve gruplar arasında serum prokalsitonin ve endokan düzeylerinde fark yoktu. Akut pankreatit ciddiyeti ile serum endokan ve prokalsitonin düzeyleri arasında korelasyon yoktu.

Sonuç: Serum endokan ve PCT düzeyleri, ciddi AP ve hafif AP grupları arasında anlamlı bir farklılık göstermedi. Bu nedenle, bu belirteçler AP'nin ciddiyetini belirlemek için ek fayda sağlayamayabilir.

Anahtar Kelimeler: akut pankreatit, ciddiyet, serum endokan ve prokalsitonin

Abstract

Object: Scoring systems and imaging methods could not provide sufficient information to determine the severity of acute pancreatitis (AP), other parameters are required. Inflammation plays an important role in the pathogenesis of acute pancreatitis and inflammation markers may be important for determining the severity of AP.

Methods: Fifty-two consecutive adult patients (>18 years) with a first AP episode were prospectively included in the study. The severity of acute pancreatitis was determined according to Revised Atlanta criteria. Circulating endocan and procalcitonin (PCT) levels were measured using ELISA.

Results: Fifty-two consecutive adult patients with a first episode of AP who had been divided into two groups according to the severity of their AP; 25 were assigned to the mild- AP group (48%) and 27 to the moderate-severe AP group (52%). The mean patient age and ratio female gender were significantly higher in the moderate - severe AP group than the mild AP group (respectively, $p = 0.04$ and 0.02). However, the groups did not differ significantly with regard to biochemical parameters and there was no difference in serum procalcitonin and endocan levels between the groups. There was no correlation between the severity of AP and serum endocan or procalcitonin levels.

Conclusion: Serum endocan and PCT levels did not significantly differ between the moderate - severe AP and mild AP groups. Therefore, these markers may not provide additional benefits for determining the severity of AP.

Key words: acute pancreatitis, severity, serum endocan and procalcitonin,



Introduction

Acute pancreatitis (AP) is an inflammatory condition that represents a spectrum of diseases ranging from those with mild, self-limiting course to severe cases such as fulminant illnesses that result in multiple organ dysfunction syndrome. AP has still a high risk of in-hospital mortality, particularly in severe cases over recent decades, due to its lack of a specific treatment regimen¹. Endothelial cell-specific molecule 1 (endocan) is a soluble proteoglycan, mainly secreted by vascular endothelial cells. The relationship between serum endocan levels with other inflammatory parameters (e.g., white blood cells and high-sensitivity C-reactive protein) supporting its role in systemic inflammation². Increased circulating endocan levels have been demonstrated in several diseases such as type 2 diabetes, hypertension, hypothyroidism, obstructive sleep apnea syndrome, and coronary artery disease, in various cancers such as hepatocellular carcinoma, renal cell carcinoma, and in systemic inflammatory diseases such as systemic lupus erythematosus^{3,4}.

Procalcitonin (PCT) is a biochemical marker produced by the parafollicular C cells of the thyroid. Several previous studies have shown that PCT is superior to C-reactive protein, interleukin-6, and leukocyte counts in the early diagnosis of bacterial infections and is a highly specific marker of sepsis⁵. Elevated serum PCT correlates closely with inflammatory responses that are secondary to microbial infections. PCT has been observed as an early predictor of the severity and development of infected pancreatic necrosis in patients with acute pancreatitis^{6,9}.

Our study aims to investigate the relationship between serum endocan and procalcitonin levels and the severity of AP and its effect on in-hospital mortality. No study has yet assessed the relationship between serum PCT and endocan concentration and the severity of AP.

Material and methods

This study was approved by the local ethics committee of the Recep Tayyip Erdogan University-Hospital and the subjects gave informed oral and written consent before inclusion in the study. Fifty-two consecutive adult patients (>18 years) with a first episode of AP who were admitted to our emergency internal medicine department over a 20-month period (2015–2017) were prospectively included in the study and AP was defined if a patient had the presence of two of the three following criteria: 1) abdominal pain consistent with the disease, 2) serum amylase and/or lipase greater than three times the normal upper limit, and/or 3) abdominal imaging (transabdominal ultrasound and/or contrast-enhanced computed tomographic) findings in accordance with AP. Alcohol-induced AP was defined as daily consumption exceeding 30 g of alcohol for men, 20 g for women, or 50 g of alcohol/day one month prior to hospitalisation in accordance with the guidelines for alcohol consumption as issued by the Danish Medical Health Authorities¹⁰, accompanied by the exclusion of gallstones in at least two of the following examinations: ultrasound (US), contrast-enhanced computerised tomography (CT) scan, and magnetic resonance imaging (MRI). Gallstone-induced AP was defined as a plasma level of aspartate aminotransferase (ASAT) >150 U/l in combination with the presence of gallstones or sludge identified via US MRI or endoscopic retrograde cholangiopancreatography (ERCP). The severity of acute pancreatitis was determined according to Revised Atlanta criteria. Moderate and severe AP were analysed together because of low number of patients in severe – AP. Exclusion criteria were: pancreatic calcifications, cysts or other signs of chronic pancreatic defect; impaired glucose tolerance or type 1/type 2 diabetes; hypertension, hyperlipidaemia, active or chronic liver or renal failure, or congestive heart failure; a

history of coronary artery disease, or acute infection (within the previous 14 days); the presence of any chronic inflammatory and autoimmune disease, and known malignancy.

Blood samples for endocan from patients were collected in plain tubes and serum was separated after centrifugation at 1500g for 10 minutes and stored at 80°C until analysis. Blood samples from calcium-EDTA tubes were analysed in an autoanalyser and Endocan levels were determined using a commercially available sandwich enzyme-linked immunosorbent assay (ELISA) kit with high sensitivity and specificity for the detection of human endocan (Bester, Wuhan, China).

Samples for PCT were centrifuged at 3,000 rpm for 10 minutes, and the serum was stored at -20°C until tested. PCT levels were measured with LUMItestPCT, an immunoluminometric assay manufactured by BRAHMS Diagnostica GmbH (Berlin, Germany). The assay's analytic sensitivity was 0.1 ng/ml and the functional sensitivity was approximately 0.3 ng/ml.

Statistical Analysis

Statistical analysis was performed using SPSS 21 (SPSS Inc., Chicago, Illinois). Data were tested for the normality of distribution using the Kolmogorov-Smirnov test. Continuous variables were presented as means with the standard deviation and categorical variables were presented as frequencies with percentages. Continuous variables between the two groups were compared using Student's t test for normally distributed data and the Mann-Whitney U test for non-normally distributed data, while categorical parameters were evaluated by chi-squared (2) test. Pearson rank tests were used to indicate the correlation of the severity of AP with endocan and PCT levels and a two-tailed $P \leq 0.05$ was considered significant

Results

Fifty-two consecutive adult patients (>18 years) with a first episode of AP were divided into two groups according to the severity of AP, meaning that 25 were assigned to the mild-AP group (48%) and 27 to the moderate - severe AP group (52%). Alcohol was the only cause of AP in three (5.7%) patients, gallstones in 40 (76.9%) and others causes (e.g. cancer and hypertriglyceridemia) in the remaining nine (17.4%). No patient required treatment with an open surgical procedure.

The groups demographic and clinical characteristics are presented in Table 1. The mean patient age and ratio of female gender was significantly higher in the moderate - severe AP group than in the mild AP group (respectively, $p = 0.04$ and 0.02). However, the groups did not differ significantly with regard to biochemical parameters. In addition, there was no difference in the serum procalcitonin and endocan levels between the groups and there was no correlation between the severity of AP and serum endocan or procalcitonin levels.





Table 1: The demographic and clinical characteristics of groups

	Mild acute pancreatitis (n=33)	Severe acute pancreatitis (n=19)	P value
Age, years	65,2±16,6	76,9±7,8	0,006
Female n, %	16(48,5)	13(68,4)	0,16
Etiology, n, %			0,42
Alcohol	2(6,1)	1(5,3)	
Gallstone	27(81,8)	13(68,4)	
Others	4(12,1)	5(26,3)	
Organ failure (n, %)	-	2(10,5)	
Glucose (mg/dl)	133,3±47,2	157,2±47,7	0,08
WBC count (103/L)	12668±4757	14596±1344	0,45
Hgb, g/dl	13,3±1,5	13,2±1,6	0,81
PLT count (103/L)	243±71	225±73	0,38
BUN, mmol/L	40,7±18,7	46,7±11,6	0,21
Cr, mg/L	0,91±0,36	0,90±0,23	0,91
CRP, mg/L	5,0±2,5	5,3±2,8	0,95
ALT, U/L	146,5± 29,1	174,7±35,5	0,59
AST, U/L	140,0±26,6	187,9±37,0	0,29
GGT, U/L	149,3±21,9	323,8±76,5	0,09
PCT, ng/dL	2,46±1,02	5,20±2,87	0,38
Endocan, ng/dl	9,8±6,0	10,8±5,9	0,56

WBC = white blood cell, Hgb = Haemoglobin, PLT = platelet, CRP = C-reactive protein, ALT = alanine aminotransferase, AST = aspartate aminotransferase, GGT = gamma-glutamyltransferase, PCT = procalcitonin, BUN = blood urea nitrogen, Cr = creatinine

Three patients (5.7%) died during the first 10 days, two of whom were in the moderate - severe AP group due to organ failure and the other was in the mild AP group due to cancer. The serum endocan and procalcitonin levels were higher among the patients with AP who died ($p=0.05$ and $p<0,001$, respectively). However, serum endocan and procalcitonin levels did not predict death in logistic regression analysis.

Table 2: Correlation analysis between Ransons core and serum endocan and PCT levels in acute pancreatitis

	Correlation coefficient	P value
Serum Endocan	r: 0,172	0,22
Serum PCT	r: 0,091	0,52

PCT: procalcitonin

Discussion

In this study, we found that there was no relationship between severity of AP and serum levels of endocan and procalcitonin. In addition, these biochemical markers did not predict death secondary to AP.

Prediction of severity plays an important role in the management of acute pancreatitis. Severe AP occurs in approximately 15–20% of patients¹¹. The early recognition of patients is crucial to prevent morbidity and mortality associated with severity. The 50% mortality relationship with severe acute pancreatitis could be decreased to 8% through early recognition¹².

It is difficult for physicians to predict which patients with AP will develop severe symptoms. Although several scoring systems have been developed to predict the severity of acute pancreatitis, these have limitations and provide little additional information for the assessment of patients¹³. Imaging techniques can not reliably establish severity in the early period of AP, as necrosis is usually absent upon admission and may only occur after 48 h¹⁴. Scoring systems and imaging methods could not provide sufficient information to determine the severity of AP, other parameters are required. The role of the inflammatory process in the basic pathophysiology of AP means that inflammatory markers have been investigated in AP. Inflammatory mediators such as tumour necrosis factor- (TNF-), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), platelet activating factor (PAF), intercellular adhesion molecule-1 (ICAM-1), growth related oncogene- α /cytokine- induced neutrophil chemoattractant (GRO- /CINC), monocyte chemoattractant protein-1 (MCP-1), interleukin 10 (IL-10), complement component C5a, substance P, hydrogen sulfide (H₂S), and neutral endopeptidase (NEP) were investigated¹⁵⁻¹⁷. However, these mediators are not practically available or consistently accurate for severity predictions in patients with AP.

Neutrophil elastase (NE) is a serine proteinase in the same family as chymotrypsin and secreted by neutrophils and macrophages during inflammation. Several studies that investigated the plasma concentrations of NE have demonstrated that it plays a role in the development of AP^{18,19}. In a study that investigated the role of neutrophil elastase in predicting the severity of acute pancreatitis, mean NE activity was significantly higher in patients with predicted severe AP than in those with predicted mild AP (20). In our study, serum endocan and procalcitonin levels did not differ between moderate-severe acute pancreatitis and mild pancreatitis. This situation may suggest that the mechanism of inflammation in various diseases may also differ. Serum PCT is secreted in the secondary inflammatory response to microbial infections, whereas endocan is released secondary to endothelial dysfunction and atherosclerosis.

Our study has several limitations; first, the sample size was relatively small, and we had no control group. Second, a single measurement of endocan and PCT may not reflect the lifetime status.

In conclusion, serum endocan and PCT levels did not differ significantly between severe AP and mild AP. Therefore, these markers may not provide additional benefit for determining the severity of AP.

Conflict of Interest:

Authors declare no competing interest

Acknowledgments:

No financial support was received for this paper.



Journal of Human Rhythm
2018;4(2):111-116

POLAT et al.

The Severity of Acute Pancreatitis
and Serum Endocan



POLAT et al.

The Severity of Acute Pancreatitis
and Serum Endocan

1. Goldacre MJ, Roberts SE. Hospital admission for acute pancreatitis in an English population, 1963 – 98: database study of incidence and mortality . *BMJ* 2004 ; 328 : 1466 – 9.
2. Gok M, Kundi H, Kiziltunc E, Topcuoglu C, Ornek E. Endocan Levels and Coronary Collateral Circulation in Stable Angina Pectoris: A Pilot Study. *Angiology*. 2017 Jan 1;3319717703835. doi: 10.1177/0003319717703835
3. Bilir B, Ekiz Bilir B, Yilmaz I, et al. Association of apelin, endoglin and endocan with diabetic peripheral neuropathy in type 2 diabetic patients. *Eur Rev Med PharmacolSci*. 2016 Mar;20(5):892-8.
4. Icli A, Cure E, Cure MC et al EndocanLevelsandSubclinicalAtherosclerosis in Patients With Systemic Lupus Erythematosus. *Angiology*. 2016 Sep;67(8):749-55.
5. Prat C, Sancho JM, Dominguez J, et al. Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. *LeukLymphoma*. 2008 Sep;49(9):1752-61.
6. Mandi Y, Farkas G, Takacs T, Boda K, Lonovics J. Diagnostic relevance of procalcitonin, IL-6, and sICAM-1 in the prediction of infected necrosis in acute pancreatitis. *Int J Pancreatol* 2000;28:41-9.
7. Riché FC, Cholley BP, Laisné MJ, et al. Inflammatory cytokines, C reactive protein, and procalcitonin as early predictors of necrosis/infection in acute necrotizing pancreatitis. *Surgery*. 2003 Mar;133(3):257-62.
8. Olah A, Belagyi T, Issekutz A, Makay R, Zaborszky A. Value of procalcitonin quick test in the differentiation between sterile and infected forms of acute pancreatitis. *Hepatogastroenterology* 2005;52:243-5.
9. Ammori BJ, Becker KL, Kite P, et al. Calcitonin precursors: early markers of gut barrier dysfunction in patients with acute pancreatitis. *Pancreas*. 2003 Oct;27(3):239-43.
10. Danish Medical Health Authorities. *Alkohol*. Sundhedsstyrelsen, Danish. Available from: <http://www.sst.dk/>.
11. Banks PA , Freeman ML . Practice guidelines in acute pancreatitis . *Am J Gastroenterol*2006 ; 101 : 2379 – 400
12. Werner J, Feuerbach S, Uhl W, Büchler MW. Management of acute pancreatitis: From surgery to interventional intensive care. *Gut* 2005;54:426-36
13. TennerS .Initial management of acute pancreatitis: critical decisions during the first 72 hours . *Am J Gastroenterol*2004 ; 99 : 2489 – 94
14. Balthazar EJ, Robinson DL, Megibow AJ, Ranson JH. Acute pancreatitis: value of CT in establishing prognosis. *Radiology*. 1990 Feb;174(2):331-6.
15. Bhatia M, Brady M, Shokuhi S, Christmas S, Neoptolemos JP, Slavin J: Inflammatory mediators in acute pancreatitis. *J Pathol*. 2000;190:117–125
16. Bhatia M, Moochhala S: Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. *J Pathol* 2004;202:145–156
17. Bhatia M, Wong FL, Cao Y, et al. Pathophysiology of acute pancreatitis. *Pancreatology* 2005;5(2–3):132–144
18. Dominguez-Munoz JE, Villanueva A , Larino J et al. Accuracy of plasma levels of polymorphonuclear elastase as early prognostic marker of acute pancreatitis in routine clinical conditions. *Eur J GastroenterolHepatol*2006 ; 18 : 79 – 83 .
19. Dominguez-Munoz JE, Carballo F , Garcia MJ , et al . Monitoring of serum proteinase–antiproteinase balance and systemic inflammatory response in prognostic evaluation of acute pancreatitis .Results of a prospective multicenter study. *DigDisSci*1993 ; 38 : 507 – 13 .
20. Novovic S, Andersen AM, Nord M, et al. Activity of neutrophil elastase reflects the progression of acute pancreatitis. *Scand J ClinLabInvest*. 2013 Sep;73(6):485-93.